Xinxing Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xinxing Li has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Zhiqian Hu
Department of General Surgery, Tongji Hospital, School of Medicine Tongji University Shanghai China
9 shared publications Jiexuan Wang
Department of General Surgery, Tongji Hospital, Tongji University School of Medicine, Shanghai, China
4 shared publicationsLin Zhu
Department of General Surgery, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China
4 shared publicationsWenqiang Wang
Department of General Surgery, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China
4 shared publicationsQiang Sun
Department of Gastrointestinal Surgery, Changzheng Hospital, Naval Medical University (Second Military Medical University), Shanghai, China
3 shared publicationsWei Zhang
Department of Gastrointestinal Surgery, Tongji Hospital, Tongji University School of Medicine, Shanghai, P. R. China
3 shared publications
Latest Publications
- 8 November 2026
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 53 (11)
Context‐Dependent Associations of GCN1 With Malignant Phenotypes, Immune‐Related Features and Prognosis in Colorectal Cancer
Objective: This study aimed to investigate the expression pattern, clinical significance, immune association and biological function of general control nonderepressible 1 (GCN1) in colorectal cancer (CRC). Methods: Gene expression and clinical data from 1603 CRC patients were obtained from TCGA and E‐MTAB‐12862 datasets, with external validation using GEO cohorts. Tumour immune cell proportions were estimated using the CIBERSORT and ESTIMATE algorithms. Predicted drug responses were assessed using the oncoPredict package based on the GDSC database. In vitro functional experiments, including MTT proliferation assays and transwell migration and invasion assays, were conducted in HCT116 and HT29 cell lines following GCN1 knockdown. Results: GCN1 was significantly upregulated in CRC tissues compared with normal tissues. Higher GCN1 expression was associated with improved overall survival in early‐stage CRC and lower tumour stage. Immune microenvironment analysis revealed that tumours with high GCN1 expression showed computationally inferred enrichment of antitumor immune cell populations and reduced immunosuppressive components, along with lower TIDE scores. Functional enrichment analyses indicated that GCN1 was involved in pathways related to cell cycle regulation, DNA replication and epithelial–mesenchymal transition (EMT). Knockdown of GCN1 significantly inhibited CRC cell proliferation, migration and invasion while modulating EMT and cell cycle‐related proteins. Drug sensitivity prediction further indicated that tumours with high GCN1 expression exhibited lower computationally inferred IC50 values for several commonly used chemotherapeutic agents, including 5‐fluorouracil, oxaliplatin, paclitaxel and docetaxel. Conclusion: Our findings suggest that GCN1 may exhibit context‐dependent associations in CRC. While in vitro experiments support a tumour cell‐intrinsic role of GCN1 in regulating malignant phenotypes through EMT‐ and cell cycle‐related processes, higher GCN1 expression at the tissue level was also associated with favourable clinical and immune‐related features. These observations suggest that GCN1 may serve as a potential prognostic indicator and warrant further mechanistic investigation.
- 8 November 2026
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 53 (11)
Context‐Dependent Associations of GCN1 With Malignant Phenotypes, Immune‐Related Features and Prognosis in Colorectal Cancer
Objective: This study aimed to investigate the expression pattern, clinical significance, immune association and biological function of general control nonderepressible 1 (GCN1) in colorectal cancer (CRC). Methods: Gene expression and clinical data from 1603 CRC patients were obtained from TCGA and E‐MTAB‐12862 datasets, with external validation using GEO cohorts. Tumour immune cell proportions were estimated using the CIBERSORT and ESTIMATE algorithms. Predicted drug responses were assessed using the oncoPredict package based on the GDSC database. In vitro functional experiments, including MTT proliferation assays and transwell migration and invasion assays, were conducted in HCT116 and HT29 cell lines following GCN1 knockdown. Results: GCN1 was significantly upregulated in CRC tissues compared with normal tissues. Higher GCN1 expression was associated with improved overall survival in early‐stage CRC and lower tumour stage. Immune microenvironment analysis revealed that tumours with high GCN1 expression showed computationally inferred enrichment of antitumor immune cell populations and reduced immunosuppressive components, along with lower TIDE scores. Functional enrichment analyses indicated that GCN1 was involved in pathways related to cell cycle regulation, DNA replication and epithelial–mesenchymal transition (EMT). Knockdown of GCN1 significantly inhibited CRC cell proliferation, migration and invasion while modulating EMT and cell cycle‐related proteins. Drug sensitivity prediction further indicated that tumours with high GCN1 expression exhibited lower computationally inferred IC50 values for several commonly used chemotherapeutic agents, including 5‐fluorouracil, oxaliplatin, paclitaxel and docetaxel. Conclusion: Our findings suggest that GCN1 may exhibit context‐dependent associations in CRC. While in vitro experiments support a tumour cell‐intrinsic role of GCN1 in regulating malignant phenotypes through EMT‐ and cell cycle‐related processes, higher GCN1 expression at the tissue level was also associated with favourable clinical and immune‐related features. These observations suggest that GCN1 may serve as a potential prognostic indicator and warrant further mechanistic investigation.
- Open Access
- 10 March 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
Copy number alteration fingerprint predicts the clinical response of oxaliplatin-based chemotherapy in metastatic colorectal cancer
Oxaliplatin-based chemotherapy is a standard treatment for metastatic colorectal cancer (mCRC), yet accurate biomarkers to identify responders remain lacking. In this study, we developed and validated a genomic copy number alteration (CNA)-based biomarker to predict clinical response to oxaliplatin-based chemotherapy. A total of 297 samples were collected, and shallow sequencing was employed to extract CNA features. The resulting model named “CNA fingerprint” is an XGBoost model trained using 7 CNA features. The model was validated across three independent test cohorts from two centers, achieving area under the receiver operating characteristic curve (AUC) of 0.87, 0.87, and 0.85, respectively. The primary predictor was the number of DNA segments with high absolute copy numbers. Our findings suggest that the CNA fingerprint could be used as biomarker for oxaliplatin-based chemotherapy response prediction in mCRC. Further prospective clinical trials are warranted to evaluate CNA fingerprint’s performance in clinical applications.
- 10 March 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
Open AccessCopy number alteration fingerprint predicts the clinical response of oxaliplatin-based chemotherapy in metastatic colorectal cancer
Oxaliplatin-based chemotherapy is a standard treatment for metastatic colorectal cancer (mCRC), yet accurate biomarkers to identify responders remain lacking. In this study, we developed and validated a genomic copy number alteration (CNA)-based biomarker to predict clinical response to oxaliplatin-based chemotherapy. A total of 297 samples were collected, and shallow sequencing was employed to extract CNA features. The resulting model named “CNA fingerprint” is an XGBoost model trained using 7 CNA features. The model was validated across three independent test cohorts from two centers, achieving area under the receiver operating characteristic curve (AUC) of 0.87, 0.87, and 0.85, respectively. The primary predictor was the number of DNA segments with high absolute copy numbers. Our findings suggest that the CNA fingerprint could be used as biomarker for oxaliplatin-based chemotherapy response prediction in mCRC. Further prospective clinical trials are warranted to evaluate CNA fingerprint’s performance in clinical applications.
- Open Access
- 18 December 2025
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1)
Immune-related deubiquitylation spectrum of microsatellite stability colorectal cancer reveals USP7 as a potential immunotherapeutic target
The efficacy of immune checkpoint inhibitors (ICIs) in microsatellite stable colorectal cancer (MSS CRC) remains limited, highlighting an urgent need for p
- 18 December 2025
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1)
Open AccessImmune-related deubiquitylation spectrum of microsatellite stability colorectal cancer reveals USP7 as a potential immunotherapeutic target
The efficacy of immune checkpoint inhibitors (ICIs) in microsatellite stable colorectal cancer (MSS CRC) remains limited, highlighting an urgent need for p
- Open Access
- 17 December 2025
- Published by Wiley in The Journal of Gene Medicine
- Vol. 27 (12) , e70065
Tumor Immune Contexture Model Predicts Prognosis and Immunotherapy Response in Gastric Cancer
Background: Gastric cancer (GC) is highly heterogeneous, and current prognostic models fail to fully capture tumor immune characteristics, limiting personalized treatment. This study introduces the Tumor Immune Environment Score (TIES), an immune‐based prognostic model designed to enhance risk stratification and predict response to immunotherapy. Methods: Transcriptomic and clinical data from seven GC cohorts, comprising a total of 1487 patients, were analyzed. The training cohort included GSE15459, GSE62254, GSE84433, and GSE13861, while the validation cohort comprised GSE26899, GSE26901, and TCGA‐STAD. Immune‐related gene signatures were quantified using ssGSEA and subsequently analyzed via LASSO and Cox regression. Clinical applicability was quantified using decision‐curve analysis (DCA) and reclassification metrics (category‐free NRI/IDI) for TIES versus TIES + pathological stage. Immunotherapy response was assessed using data from GSE183924, and its associations with immune characteristics, molecular alterations, and drug sensitivity were investigated. For experimental confirmation, we established a 12‐gene RT‐qPCR panel in 30 institutional GC specimens and computed a weighted qPCR surrogate (qTIES). Results: A high TIES was associated with worse OS (HR = 2.44, p < 0.001) and DFS (HR = 2.25, p < 0.001). TIES was an independent prognostic factor and demonstrated superior predictive accuracy compared to TNM staging (AUC = 0.75–0.79 vs. 0.61–0.64, p < 0.001). Integrating clinical‐pathological features with TIES significantly enhanced predictive performance (AUC = 0.75–0.78 vs. 0.61–0.63, p < 0.01). A low TIES was indicative of an immune‐inflamed subtype, characterized by a higher TMB ( p < 0.01) and a greater likelihood of response to immunotherapy (HR = 0.24, p = 0.014). TIES outperformed TIDE in predicting immunotherapy outcomes, achieving a higher OS C‐index (0.780 vs. 0.743) and DFS C‐index (0.664 vs. 0.610). At 3 years, TIES + stage yielded a greater net benefit than TIES alone across clinically relevant thresholds (DCA) and improved NRI/IDI.The qPCR panel reproduced axis biology (CSR/TGF‐βincreased with NK/Th2 decreased), correlated with pathological stage, stratified OS/DFS by Kaplan–Meier, and showed 3‐year discrimination. Conclusion: TIES represents a robust immune‐based prognostic tool for GC, facilitating improved risk stratification and immunotherapy response prediction. Its integration into clinical practice, particularly in combination with clinical‐pathological features, may enhance personalized treatment strategies and improve patient outcomes.
- 17 December 2025
- Published by Wiley in The Journal of Gene Medicine
- Vol. 27 (12) , e70065
Open AccessTumor Immune Contexture Model Predicts Prognosis and Immunotherapy Response in Gastric Cancer
Background: Gastric cancer (GC) is highly heterogeneous, and current prognostic models fail to fully capture tumor immune characteristics, limiting personalized treatment. This study introduces the Tumor Immune Environment Score (TIES), an immune‐based prognostic model designed to enhance risk stratification and predict response to immunotherapy. Methods: Transcriptomic and clinical data from seven GC cohorts, comprising a total of 1487 patients, were analyzed. The training cohort included GSE15459, GSE62254, GSE84433, and GSE13861, while the validation cohort comprised GSE26899, GSE26901, and TCGA‐STAD. Immune‐related gene signatures were quantified using ssGSEA and subsequently analyzed via LASSO and Cox regression. Clinical applicability was quantified using decision‐curve analysis (DCA) and reclassification metrics (category‐free NRI/IDI) for TIES versus TIES + pathological stage. Immunotherapy response was assessed using data from GSE183924, and its associations with immune characteristics, molecular alterations, and drug sensitivity were investigated. For experimental confirmation, we established a 12‐gene RT‐qPCR panel in 30 institutional GC specimens and computed a weighted qPCR surrogate (qTIES). Results: A high TIES was associated with worse OS (HR = 2.44, p < 0.001) and DFS (HR = 2.25, p < 0.001). TIES was an independent prognostic factor and demonstrated superior predictive accuracy compared to TNM staging (AUC = 0.75–0.79 vs. 0.61–0.64, p < 0.001). Integrating clinical‐pathological features with TIES significantly enhanced predictive performance (AUC = 0.75–0.78 vs. 0.61–0.63, p < 0.01). A low TIES was indicative of an immune‐inflamed subtype, characterized by a higher TMB ( p < 0.01) and a greater likelihood of response to immunotherapy (HR = 0.24, p = 0.014). TIES outperformed TIDE in predicting immunotherapy outcomes, achieving a higher OS C‐index (0.780 vs. 0.743) and DFS C‐index (0.664 vs. 0.610). At 3 years, TIES + stage yielded a greater net benefit than TIES alone across clinically relevant thresholds (DCA) and improved NRI/IDI.The qPCR panel reproduced axis biology (CSR/TGF‐βincreased with NK/Th2 decreased), correlated with pathological stage, stratified OS/DFS by Kaplan–Meier, and showed 3‐year discrimination. Conclusion: TIES represents a robust immune‐based prognostic tool for GC, facilitating improved risk stratification and immunotherapy response prediction. Its integration into clinical practice, particularly in combination with clinical‐pathological features, may enhance personalized treatment strategies and improve patient outcomes.
- Open Access
- 5 June 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-12
TET2 orchestrates YAP signaling to potentiate targetable vulnerability in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a leading cause of global cancer-associated mortality. Although various therapies have substantially ameliorated clinical outcome, patients invariably suffer from cancer relapse, highlighting the need for more optimized therapeutic strategies. Here, we report that deficiency of DNA methylcytosine dioxygenase TET2 sensitizes HCC cells to sorafenib and verteporfin treatments. Mechanistically, knockout of TET2 enhances the dephosphorylation of YAP Ser127, thus promoting its activity. RNA-seq analysis reveals that MC1R, a GPCR, is strikingly decreased upon TET2 deficiency. Furthermore, TET2 catalyzes demethylation of MC1R promoter to stimulate its transcription. MC1R subsequently boosts cAMP-PKA signaling to phosphorylate YAP Ser127 in both ligand dependent and independent manners. Importantly, deletion of MC1R accelerates tumor growth of HCC, which is reversed by the treatment of YAP-TEAD complex inhibitor verteporfin. Synergistic combination of MC1R expression driver vitamin C and its ligand α-MSH dramatically represses HCC growth. Notably, TET2-MC1R-YAP axis is evidenced in HCC specimens and plays a vital role in prognosis of HCC. Collectively, these findings not only elucidate a previously unidentified epigenetic regulatory mechanism of MC1R transcription and underscore the functional significance of MC1R signaling in tumorigenesis of HCC, but also provide potential targets and clinical strategies for HCC therapy.
- 5 June 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-12
Open AccessTET2 orchestrates YAP signaling to potentiate targetable vulnerability in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a leading cause of global cancer-associated mortality. Although various therapies have substantially ameliorated clinical outcome, patients invariably suffer from cancer relapse, highlighting the need for more optimized therapeutic strategies. Here, we report that deficiency of DNA methylcytosine dioxygenase TET2 sensitizes HCC cells to sorafenib and verteporfin treatments. Mechanistically, knockout of TET2 enhances the dephosphorylation of YAP Ser127, thus promoting its activity. RNA-seq analysis reveals that MC1R, a GPCR, is strikingly decreased upon TET2 deficiency. Furthermore, TET2 catalyzes demethylation of MC1R promoter to stimulate its transcription. MC1R subsequently boosts cAMP-PKA signaling to phosphorylate YAP Ser127 in both ligand dependent and independent manners. Importantly, deletion of MC1R accelerates tumor growth of HCC, which is reversed by the treatment of YAP-TEAD complex inhibitor verteporfin. Synergistic combination of MC1R expression driver vitamin C and its ligand α-MSH dramatically represses HCC growth. Notably, TET2-MC1R-YAP axis is evidenced in HCC specimens and plays a vital role in prognosis of HCC. Collectively, these findings not only elucidate a previously unidentified epigenetic regulatory mechanism of MC1R transcription and underscore the functional significance of MC1R signaling in tumorigenesis of HCC, but also provide potential targets and clinical strategies for HCC therapy.
- Open Access
- 20 August 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (9) , 2188-2209
Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction
While whole genome sequencing (WGS) of cell-free DNA (cfDNA) holds enormous promise for detection of molecular residual disease (MRD), its performance is limited by WGS error rate. Here we introduce AccuScan, an efficient cfDNA WGS technology that enables genome-wide error correction at single read-level, achieving an error rate of 4.2 × 10 −7 , which is about two orders of magnitude lower than a read-centric de-noising method. The application of AccuScan to MRD demonstrated analytical sensitivity down to 10 −6 circulating variant allele frequency at 99% sample-level specificity. AccuScan showed 90% landmark sensitivity (within 6 weeks after surgery) and 100% specificity for predicting relapse in colorectal cancer. It also showed 67% sensitivity and 100% specificity in esophageal cancer using samples collected within one week after surgery. When AccuScan was applied to monitor immunotherapy in melanoma patients, the circulating tumor DNA (ctDNA) levels and dynamic profiles were consistent with clinical outcomes. Overall, AccuScan provides a highly accurate WGS solution for MRD detection, empowering ctDNA detection at parts per million range without requiring high sample input or personalized reagents.
- 20 August 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (9) , 2188-2209
Open AccessUltra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction
While whole genome sequencing (WGS) of cell-free DNA (cfDNA) holds enormous promise for detection of molecular residual disease (MRD), its performance is limited by WGS error rate. Here we introduce AccuScan, an efficient cfDNA WGS technology that enables genome-wide error correction at single read-level, achieving an error rate of 4.2 × 10 −7 , which is about two orders of magnitude lower than a read-centric de-noising method. The application of AccuScan to MRD demonstrated analytical sensitivity down to 10 −6 circulating variant allele frequency at 99% sample-level specificity. AccuScan showed 90% landmark sensitivity (within 6 weeks after surgery) and 100% specificity for predicting relapse in colorectal cancer. It also showed 67% sensitivity and 100% specificity in esophageal cancer using samples collected within one week after surgery. When AccuScan was applied to monitor immunotherapy in melanoma patients, the circulating tumor DNA (ctDNA) levels and dynamic profiles were consistent with clinical outcomes. Overall, AccuScan provides a highly accurate WGS solution for MRD detection, empowering ctDNA detection at parts per million range without requiring high sample input or personalized reagents.
- Open Access
- 26 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 44 (7) , 713-717
Single‐cell landscape of malignant ascites from patients with metastatic colorectal cancer
- 26 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 44 (7) , 713-717
Open AccessSingle‐cell landscape of malignant ascites from patients with metastatic colorectal cancer
- Open Access
- 29 June 2023
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 21 (1) , 1-14
Discovery of extracellular vesicle-delivered miR-185-5p in the plasma of patients as an indicator for advanced adenoma and colorectal cancer
Background: We aimed to evaluate whether extracellular vesicles (EV)-derived microRNAs (miRNAs) can be used as biomarkers for advanced adenoma (AA) and colorectal cancer (CRC). Methods: We detected the changes in the plasma EV-delivered miRNA profiles in healthy donor (HD), AA patient, and I-II stage CRC patient groups using miRNA deep sequencing assay. We performed the TaqMan miRNA assay using 173 plasma samples (two independent cohorts) from HDs, AA patients, and CRC patients to identify the candidate miRNA(s). The accuracy of candidate miRNA(s) in diagnosing AA and CRC was determined using the area under the receiver-operating characteristic curve (AUC) values. Logistic regression analysis was performed to evaluate the association of candidate miRNA(s) as an independent factor for the diagnosis of AA and CRC. The role of candidate miRNA(s) in the malignant progression of CRC was explored using functional assays. Results: We screened and identified four prospective EV-delivered miRNAs, including miR-185-5p, which were significantly upregulated or downregulated in AA vs. HD and CRC vs. AA groups. In two independent cohorts, miR-185-5p was the best potential biomarker with the AUCs of 0.737 (Cohort I) and 0.720 (Cohort II) for AA vs. HD diagnosis, 0.887 (Cohort I) and 0.803 (Cohort II) for CRC vs. HD diagnosis, and 0.700 (Cohort I) and 0.631 (Cohort II) for CRC vs. AA diagnosis. Finally, we demonstrated that the upregulated expression of miR-185-5p promoted the malignant progression of CRC. Conclusion: EV-delivered miR-185-5p in the plasma of patients is a promising diagnostic biomarker for colorectal AA and CRC. Trial registration The study protocol was approved by the Ethics Committee of Changzheng Hospital, Naval Medical University, China (Ethics No. 2022SL005, Registration No. of China Clinical Trial Registration Center: ChiCTR220061592).
- 29 June 2023
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 21 (1) , 1-14
Open AccessDiscovery of extracellular vesicle-delivered miR-185-5p in the plasma of patients as an indicator for advanced adenoma and colorectal cancer
Background: We aimed to evaluate whether extracellular vesicles (EV)-derived microRNAs (miRNAs) can be used as biomarkers for advanced adenoma (AA) and colorectal cancer (CRC). Methods: We detected the changes in the plasma EV-delivered miRNA profiles in healthy donor (HD), AA patient, and I-II stage CRC patient groups using miRNA deep sequencing assay. We performed the TaqMan miRNA assay using 173 plasma samples (two independent cohorts) from HDs, AA patients, and CRC patients to identify the candidate miRNA(s). The accuracy of candidate miRNA(s) in diagnosing AA and CRC was determined using the area under the receiver-operating characteristic curve (AUC) values. Logistic regression analysis was performed to evaluate the association of candidate miRNA(s) as an independent factor for the diagnosis of AA and CRC. The role of candidate miRNA(s) in the malignant progression of CRC was explored using functional assays. Results: We screened and identified four prospective EV-delivered miRNAs, including miR-185-5p, which were significantly upregulated or downregulated in AA vs. HD and CRC vs. AA groups. In two independent cohorts, miR-185-5p was the best potential biomarker with the AUCs of 0.737 (Cohort I) and 0.720 (Cohort II) for AA vs. HD diagnosis, 0.887 (Cohort I) and 0.803 (Cohort II) for CRC vs. HD diagnosis, and 0.700 (Cohort I) and 0.631 (Cohort II) for CRC vs. AA diagnosis. Finally, we demonstrated that the upregulated expression of miR-185-5p promoted the malignant progression of CRC. Conclusion: EV-delivered miR-185-5p in the plasma of patients is a promising diagnostic biomarker for colorectal AA and CRC. Trial registration The study protocol was approved by the Ethics Committee of Changzheng Hospital, Naval Medical University, China (Ethics No. 2022SL005, Registration No. of China Clinical Trial Registration Center: ChiCTR220061592).
- Open Access
- 14 March 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1001819
Interaction between the intestinal flora and the severity of diversion colitis after low anterior resection of rectal cancer
Background: Diversion colitis (DC) is nonspecific inflammation of the distal intestinal mucosa following disruption of colonic continuity with colonic dysfunction. The colonscopic score is a good tool for differentiating the severity of patients with DC. At present, no studies have analyzed the pathogenesis of DC from the perspective of the diversity and and differences of intestinal flora.Methods: Retrospective study: Clinical information were collected from patients with low rectal cancer admitted to the Department of Anorectal Surgery, Changzheng Hospital, from April 2017 to April 2019. These patients underwent laparoscopic low anterior resection (LAR) combined with terminal ileum enterostomy (dual-chamber). We used chi-square test to comparethe clinical baseline information, clinical symptoms, and colonscopic characteristics between different severity of DC. Propsective oberservational study: We recruited 40 patients with laparoscopic anterior low resection combined with terminal ileum enterostomy and they were further classified into mild group and severe group according to the scores of colonscopic examinations for DC. 16s-rDNA sequencing was carried out to analyze the diversity and and differences of intestinal flora in the intestinal lavage fluid of the two groups.Results: In retrospective study, we found that age, BMI, history of diabetes, and symptoms associated with the stoma state were the independent risk factors that affect DC severity (PP<0.05), which was consistent with our results of differentiating the severity of DC under endoscopy; In propsective oberservational study, 40 patients with low rectal cancer recruited by sample size calculation, 23 were in the mild group and 17 in the severe group. The results of 16s-rDNA sequencing showed that intestinal flora with high enrichment values primarily consisted of Bifidobacteriales and Prevotella in mild group, whereas that in the severe group consisted of Providencia and Dorea. The functional predictions on such two types of intestinal flora were mainly focused on lipid synthesis, glycan synthesis, metabolism, and amino acid metabolism pathways.Conclusion: After ileostomy closure surgery, a series of severe clinical symptoms might appear in DC patients. There are significant differences in local and systemic inflammatory responses, composition of intestinal flora between DC patients with different colonscopic scores, which provide a basis for the clinical interventional treatment for DC in patients with permanent stoma.
- 14 March 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1001819
Open AccessInteraction between the intestinal flora and the severity of diversion colitis after low anterior resection of rectal cancer
Background: Diversion colitis (DC) is nonspecific inflammation of the distal intestinal mucosa following disruption of colonic continuity with colonic dysfunction. The colonscopic score is a good tool for differentiating the severity of patients with DC. At present, no studies have analyzed the pathogenesis of DC from the perspective of the diversity and and differences of intestinal flora.Methods: Retrospective study: Clinical information were collected from patients with low rectal cancer admitted to the Department of Anorectal Surgery, Changzheng Hospital, from April 2017 to April 2019. These patients underwent laparoscopic low anterior resection (LAR) combined with terminal ileum enterostomy (dual-chamber). We used chi-square test to comparethe clinical baseline information, clinical symptoms, and colonscopic characteristics between different severity of DC. Propsective oberservational study: We recruited 40 patients with laparoscopic anterior low resection combined with terminal ileum enterostomy and they were further classified into mild group and severe group according to the scores of colonscopic examinations for DC. 16s-rDNA sequencing was carried out to analyze the diversity and and differences of intestinal flora in the intestinal lavage fluid of the two groups.Results: In retrospective study, we found that age, BMI, history of diabetes, and symptoms associated with the stoma state were the independent risk factors that affect DC severity (PP<0.05), which was consistent with our results of differentiating the severity of DC under endoscopy; In propsective oberservational study, 40 patients with low rectal cancer recruited by sample size calculation, 23 were in the mild group and 17 in the severe group. The results of 16s-rDNA sequencing showed that intestinal flora with high enrichment values primarily consisted of Bifidobacteriales and Prevotella in mild group, whereas that in the severe group consisted of Providencia and Dorea. The functional predictions on such two types of intestinal flora were mainly focused on lipid synthesis, glycan synthesis, metabolism, and amino acid metabolism pathways.Conclusion: After ileostomy closure surgery, a series of severe clinical symptoms might appear in DC patients. There are significant differences in local and systemic inflammatory responses, composition of intestinal flora between DC patients with different colonscopic scores, which provide a basis for the clinical interventional treatment for DC in patients with permanent stoma.
- Open Access
- 23 February 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1109464
A retrospective case-series of influence of chronic hepatitis B on synchronous liver metastasis of colorectal cancer
Main point: Our retrospective analysis of a large number of cases found in patients with primary colorectal cancer (CRC) carrying positive HBsAg inhibited the occurrence of synchronous liver metastases (SLM). However, liver cirrhosis caused by non-HBV factors promoted the occurrence of SLM.Objectives: This study aimed to investigate the effect of HBV on the occurrence of synchronous liver metastases (SLM) of colorectal cancer (CRC).Methods: Univariate and multivariate analyses were used to analyze the influence of clinical parameters on the occurrence of SLM.Results: A total of 6, 020 patients with primary CRC were included in our study, of which 449 patients carrying HBsAg(+) accounted for 7.46%. 44 cases of SLM occurred in the HBsAg(+) group, accounting for 9.80%, which was much lower than 13.6% (758/5571) in the HBsAg(-) group (X=5.214, P=0.022). Among CRC patients with HBsAg(-), the incidence of SLM was 24.9% and 14.9% in the group with high APRI and FIB-4 levels, respectively, which were significantly higher than that in the compared groups (12.3% and 12.5%, all P<0.05). Compared with the control group, female patients, late-onset patients, and HBV-infective patients had lower risks of SLM (HR=0.737, 95%CI: 0.614-0.883, P<0.001; HR=0.752, 95%CI: 0.603-0.943, P=0.013; HR=0.682, 95%CI: 0.473-0.961, P=0.034).Conclusions: The carriage of HBsAg(+) status inhibited the occurrence of SLM from CRC. HBV-causing liver cirrhosis did not further influence the occurrence of SLM, whereas non-HBV-factor cirrhosis promoted the occurrence of SLM. Nevertheless, this still required prospective data validation.
- 23 February 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1109464
Open AccessA retrospective case-series of influence of chronic hepatitis B on synchronous liver metastasis of colorectal cancer
Main point: Our retrospective analysis of a large number of cases found in patients with primary colorectal cancer (CRC) carrying positive HBsAg inhibited the occurrence of synchronous liver metastases (SLM). However, liver cirrhosis caused by non-HBV factors promoted the occurrence of SLM.Objectives: This study aimed to investigate the effect of HBV on the occurrence of synchronous liver metastases (SLM) of colorectal cancer (CRC).Methods: Univariate and multivariate analyses were used to analyze the influence of clinical parameters on the occurrence of SLM.Results: A total of 6, 020 patients with primary CRC were included in our study, of which 449 patients carrying HBsAg(+) accounted for 7.46%. 44 cases of SLM occurred in the HBsAg(+) group, accounting for 9.80%, which was much lower than 13.6% (758/5571) in the HBsAg(-) group (X=5.214, P=0.022). Among CRC patients with HBsAg(-), the incidence of SLM was 24.9% and 14.9% in the group with high APRI and FIB-4 levels, respectively, which were significantly higher than that in the compared groups (12.3% and 12.5%, all P<0.05). Compared with the control group, female patients, late-onset patients, and HBV-infective patients had lower risks of SLM (HR=0.737, 95%CI: 0.614-0.883, P<0.001; HR=0.752, 95%CI: 0.603-0.943, P=0.013; HR=0.682, 95%CI: 0.473-0.961, P=0.034).Conclusions: The carriage of HBsAg(+) status inhibited the occurrence of SLM from CRC. HBV-causing liver cirrhosis did not further influence the occurrence of SLM, whereas non-HBV-factor cirrhosis promoted the occurrence of SLM. Nevertheless, this still required prospective data validation.